Market Place
Sourcing Support
Bayer`s Asundexian Shows 26% Stroke Reduction
07 Feb 2026 //
INDPHARMAPOST
Bayer Presents Phase III OCEANIC-STROKE Study Results
27 Jan 2026 //
BUSINESSWIRE
Bayer Unveils Positive Phase III Anticoagulant Data
23 Nov 2025 //
BUSINESSWIRE
OCEANIC-STROKE Phase III Data Accepted At World Stroke Congress
21 Oct 2025 //
BUSINESSWIRE
Bayer`s asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes
03 Sep 2024 //
FIERCE BIOTECH
Bayer Receives U.S. FDA Fast Track Designation for asundexian
16 May 2023 //
BUSINESSWIRE
Bayer kicks off Phase III studies of oral factor XIa inhibitor asundexian
09 Feb 2023 //
BUSINESSWIRE
Bayer Initiates PIII Study for Investigational Oral FXIa Inhibitor Asundexian
28 Aug 2022 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.